LB Pharmaceuticals Reports Phase 2 Data Showing LB-102 Directly Improves Cognitive Function In Schizophrenia Patients

LB Pharmaceuticals Inc (NASDAQ: LBRX) announced new Phase 2 data from the NOVA-1 clinical trial, demonstrating that its investigational drug LB-102 significantly improves cognitive function in patients with acute schizophrenia. The analysis indicated that the cognitive benefits observed were primarily a direct effect of LB-102, a novel oral small molecule targeting D2, D3, and 5HT7 receptors. This data was presented at the Schizophrenia International Research Society meeting on March 27th in Florence, Italy.